Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides.
about
Immunoproteomics: Mass spectrometry-based methods to study the targets of the immune responseThe Human Immunopeptidome Project, a suggestion for yet another postgenome next big thingIdentification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy.Soluble plasma HLA peptidome as a potential source for cancer biomarkersMonoclonal antibody 16D10 to the C-terminal domain of the feto-acinar pancreatic protein binds to membrane of human pancreatic tumoral SOJ-6 cells and inhibits the growth of tumor xenografts.The MHC class I peptide repertoire is molded by the transcriptome.MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines.Immunoinformatics: an integrated scenario.Identification of pancreatic cancer-associated tumor antigen from HSP-enriched tumor lysate-pulsed human dendritic cells.ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.The effect of proteasome inhibition on the generation of the human leukocyte antigen (HLA) peptidome.Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface.The turnover kinetics of major histocompatibility complex peptides of human cancer cells.
P2860
Q28238379-93BA2F52-9D42-41DB-89E8-769DF26FD762Q28743282-4CFA7E27-5F94-40E2-89D9-6B0422C9473DQ30441689-EA4016FD-5F8C-4F48-BD89-7386E904C91DQ34279102-A61FECC4-FD7C-41BE-92BA-795EEB821314Q34928685-64D4E702-89DB-4453-9C0A-96690CEC0D0AQ36509857-3BA879EB-EB5F-4E29-94D8-C28B8CEFE7DAQ37709626-3309EB07-F4E5-401C-B0BF-7B726D8E4134Q37781086-09B08F1D-CBD6-4677-885D-7C6B12BDAD4EQ38437145-59017273-82D0-425D-90E4-59E9B4640F7DQ39617457-6310C039-52FD-4251-9389-0D6CDEF5468FQ43097138-BB3B0190-F2B1-4755-928B-380051BF09E4Q51583278-A9D3C97F-65DE-4A36-8057-C13428C85CDBQ53650261-2D579A28-25EF-43E1-86B8-81D60A8BD04F
P2860
Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Tumor antigens and proteomics ...... ompatibility complex peptides.
@ast
Tumor antigens and proteomics ...... ompatibility complex peptides.
@en
type
label
Tumor antigens and proteomics ...... ompatibility complex peptides.
@ast
Tumor antigens and proteomics ...... ompatibility complex peptides.
@en
prefLabel
Tumor antigens and proteomics ...... ompatibility complex peptides.
@ast
Tumor antigens and proteomics ...... ompatibility complex peptides.
@en
P2093
P2860
P1476
Tumor antigens and proteomics ...... ompatibility complex peptides.
@en
P2093
Arie Admon
Eilon Barnea
P2860
P304
P356
10.1074/MCP.R300004-MCP200
P577
2003-06-23T00:00:00Z